These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16174852)

  • 21. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
    [No Abstract]   [Full Text] [Related]  

  • 23. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Norum J
    Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trust's refusal to fund trastuzumab was "arbitrary".
    Dyer C
    BMJ; 2006 Apr; 332(7544):747. PubMed ID: 16575068
    [No Abstract]   [Full Text] [Related]  

  • 25. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 26. [Medical treatment of primary breast cancer: new targeted biological treatments].
    Andersson M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3082-4. PubMed ID: 17877953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab for early breast cancer: current status and future directions.
    Dinh P; de Azambuja E; Piccart-Gebhart MJ
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):707-17. PubMed ID: 17982412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
    Hayes DF
    J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
    [No Abstract]   [Full Text] [Related]  

  • 29. Making a case for a $2700-a-month drug.
    Sibbald B
    CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
    [No Abstract]   [Full Text] [Related]  

  • 30. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of trastuzumab for the treatment of early stage breast cancer.
    Braga S; dal Lago L; Bernard C; Cardoso F; Piccart M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1153-64. PubMed ID: 16925482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
    Hehl EM
    Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuation of trastuzumab beyond disease progression.
    Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
    J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 38. Trastuzumab in breast cancer.
    Gounaris IG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.